Leland Gershell
Stock Analyst at Oppenheimer
(4.61)
# 212
Out of 5,117 analysts
150
Total ratings
52.48%
Success rate
35.28%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $85.74 | +230.07% | 1 | Dec 23, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $35 | $13.65 | +156.41% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $29.69 | +81.88% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $12.85 | +86.77% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $9.50 | +247.37% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $7.37 | +144.23% | 5 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $31.88 | +12.92% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $47.96 | +81.40% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $20.88 | +283.14% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $47.65 | +130.85% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $75.80 | -19.53% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $400.59 | +22.32% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $10.25 | +95.12% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $110.00 | - | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $208.98 | +7.19% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $23.03 | +34.61% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.93 | +102.84% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $844.92 | -16.21% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.56 | +180.90% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $59.95 | +63.47% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $41.83 | +24.31% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $195.83 | -24.93% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.40 | +1,983.33% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $26.16 | +102.60% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.78 | +217.46% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.31 | +150,957.40% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.55 | +350.45% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $6.23 | +221.03% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $24.35 | +19.10% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $18.37 | +90.53% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.32 | +2,978.82% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.90 | +2,111.90% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.08 | +525.00% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.50 | +2,566.67% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.25 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $31.89 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.79 | +6,233.12% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.14 | - | 5 | Mar 31, 2020 |
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $85.74
Upside: +230.07%
Aardvark Therapeutics
Dec 23, 2025
Initiates: Outperform
Price Target: $35
Current: $13.65
Upside: +156.41%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $29.69
Upside: +81.88%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $12.85
Upside: +86.77%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $9.50
Upside: +247.37%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $7.37
Upside: +144.23%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $31.88
Upside: +12.92%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $47.96
Upside: +81.40%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $20.88
Upside: +283.14%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $47.65
Upside: +130.85%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $75.80
Upside: -19.53%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $400.59
Upside: +22.32%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $10.25
Upside: +95.12%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $110.00
Upside: -
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $208.98
Upside: +7.19%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $23.03
Upside: +34.61%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $4.93
Upside: +102.84%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $844.92
Upside: -16.21%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $3.56
Upside: +180.90%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $59.95
Upside: +63.47%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $41.83
Upside: +24.31%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $195.83
Upside: -24.93%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.40
Upside: +1,983.33%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $26.16
Upside: +102.60%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.78
Upside: +217.46%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.31
Upside: +150,957.40%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.55
Upside: +350.45%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $6.23
Upside: +221.03%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $24.35
Upside: +19.10%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $18.37
Upside: +90.53%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.32
Upside: +2,978.82%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.90
Upside: +2,111.90%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.08
Upside: +525.00%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.50
Upside: +2,566.67%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.25
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $31.89
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $0.79
Upside: +6,233.12%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.14
Upside: -